fbpx
 

Parkinson’s Disease

Parkinson’s disease is a chronic, progressive neurological disorder. This medical condition is caused by the destruction of nerve cells in the brain. More specifically, the brain’s basal ganglia are affected and thus dopamine secretion is reduced dramatically. The reduced production of dopamine causes irregular brain function, which in turn leads to impaired movement and other characteristic symptoms of Parkinson’s disease.

 

Diagnosis of Real Causes & Treatment of Parkinson’s Disease

  • Gradual restoration of cellular function
  • Personalized therapeutic protocols, without chemical residues and excipients
  • Treating the real causes
  • Therapeutic formulas that work alone or in combination with any other medication
  • Adopting a Molecular / Therapeutic Nutrition Plan

 

The symptoms of Parkinson’s disease can vary from individual to individual. The early symptoms of Parkinson’s include: stooped posture, difficulty in handwriting, gradual loss of smell, constipation, possible changes in the voice. As the disease progresses, more evident symptoms arise: tremor, impaired movement, stiff muscles, balance issues, speech difficulties, a “neutral” face expression and/or decreased frequency of blinking.

Parkinson Disease

 

Your specialist may recommend a specialized blood or antibodies test, an MRI scan or other molecular-level diagnostic tests to confirm the diagnosis. In most cases a consultation with a Neurologist may be suggested. Your personalized treatment plan will be based upon the diagnostic tests results, the symptoms described and your medical history overall.

Your Specialist will explain the components, duration and health benefits of your personalized treatment plan. This treatment plan may be accompanied by a Molecular Nutrition program that will be compiled after a distinct consultation with our Molecular Nutritionist and will aim towards achieving even higher levels of health and well-being along with ameliorating the symptoms of Parkinson’s disease.

Functional Corporation
Partners

References


  • National Institute of Environmental Health Sciences. Neurodegenerative diseases. Reviewed September 10, 2019. Accessed May 18, 2020.
  • Swerdlow RH. Mitochondria and mitochondrial cascades in Alzheimer’s disease. J Alzheimers Dis.2018;62(3):1403-1416.
  • García S, Martín Giménez VM, Mocayar Marón FJ, Reiter RJ, Manucha W. Melatonin and cannabinoids: mitochondrial-targeted molecules that may reduce inflammaging in neurodegenerative diseases. Histol Histopathol. 2020:18212.
  • Alzheimer’s Association. Alternative treatments. Accessed May 18, 2020.
  • Parkinson’s Foundation. Over the counter and complementary therapies. Accessed May 18, 2020.
  • National Multiple Sclerosis Society. Complementary and alternative medicines. Accessed May 18, 2020.
  • Wesselman LMP, Doorduijn AS, de Leeuw FA, et al. Dietary patterns are related to clinical characteristics in memory clinic patients with subjective cognitive decline: the SCIENCe project. Nutrients. 2019;11(5):1057.
  • Fieldhouse JLP, Doorduijn AS, de Leeuw FA, et al. A suboptimal diet is associated with poorer cognition: the NUDAD project. Nutrients. 2020;12(3):703.
  • Nolan JM, Mulcahy R, Power R, Moran R, Howard AN. Nutritional intervention to prevent Alzheimer’s disease: potential benefits of xanthophyll carotenoids and omega-3 fatty acids combined. J Alzheimers Dis. 2018;64(2):367-378.
  • Calil SRB, Brucki SMD, Nitrini R, Yassuda MS. Adherence to the Mediterranean and MIND diets is associated with better cognition in healthy seniors but not in MCI or AD. Clin Nutr ESPEN. 2018;28:201-207.
  • Power R, Prado-Cabrero A, Mulcahy R, Howard A, Nolan JM. The role of nutrition for the aging population: implications for cognition and Alzheimer’s disease. Annu Rev Food Sci Technol. 2019;10:619-639.
  • Chai B, Gao F, Wu R, et al. Vitamin D deficiency as a risk factor for dementia and Alzheimer’s disease: anupdated meta-analysis. BMC Neurol. 2019;19(1):284.
  • Bianchi VE, Herrera PF, Laura R. Effect of nutrition on neurodegenerative diseases. A systematic review.Nutr Neurosci. Published online November 4, 2019.
  • Grodzicki W, Dziendzikowska K. The role of selected bioactive compounds in the prevention of Alzheimer’s disease. Antioxidants. 2020;9(3):229.
  • AlAmmar WA, Albeesh FH, Ibrahim LM, Algindan YY, Yamani LZ, Khattab RY. Effect of omega-3 fatty acids and fish oil supplementation on multiple sclerosis: a systematic review. Nutr Neurosci. Published online August 28, 2019.
  • Wlodarek D. Role of ketogenic diets in neurodegenerative diseases (Alzheimer’s disease and Parkinson’s disease). Nutrients. 2019;11(1):169.
  • Chauhan A, Chauhan V. Beneficial effects of walnuts on cognition and brain health. Nutrients. 2020;12(2):550.
  • Valls-Pedret C, Sala-Vila A, Serra-Mir M, et al. Mediterranean diet and age-related cognitive decline: a randomized clinical trial. JAMA Intern Med. 2015;175(7):1094-1103.
  • Meng X, Zhou J, Zhao CN, Gan RY, Li HB. Health benefits and molecular mechanisms of resveratrol: a narrative review. Foods. 2020;9(3):340.
  • Huhn S, Beyer F, Zhang R, et al. Effects of resveratrol on memory performance, hippocampus connectivity and microstructure in older adults – a randomized controlled trial. Neuroimage. 2018;174:177-190.
  • Evans HM, Howe PR, Wong RH. Effects of resveratrol on cognitive performance, mood and cerebrovascular function in post-menopausal women: a 14-week randomised placebo-controlled intervention trial. Nutrients. 2017;9(1):27.
  • Liu H, Ye M, Guo H. An updated review of randomized clinical trials testing the improvement of cognitive function of Ginkgo biloba extract in healthy people and Alzheimer’s patients. Front Pharmacol. 2020;10:1688.
  • Power R, Coen RF, Beatty S, et al. Supplemental retinal carotenoids enhance memory in healthy individuals with low levels of macular pigment in a randomized, double-blind, placebo-controlled clinical trial. J Alzheimers Dis. 2018;61(3):947-961.
  • Lee DH, Chon J, Kim Y, et al. Association between vitamin D deficiency and cognitive function in the elderly Korean population: a Korean frailty and aging cohort study. Medicine (Baltimore). 2020;99(8):e19293.
  • Feige J, Moser T, Bieler L, Schwenker K, Hauer L, Sellner J. Vitamin D supplementation in multiple sclerosis: a critical analysis of potentials and threats. Nutrients. 2020;12(3):783.
  • Kouchaki E, Afarini M, Abolhassani J, et al. High-dose ?-3 fatty acid plus vitamin D3 supplementation affects clinical symptoms and metabolic status of patients with multiple sclerosis: a randomized controlled clinical trial. J Nutr. 2018;148(8):1380-1386.
  • Martínez-Lapiscina EH, Clavero P, Toledo E, et al. Mediterranean diet improves cognition: the PREDIMED-NAVARRA randomised trial. J Neurol Neurosurg Psychiatry. 2013;84(12):1318-1325.
  • Lee JE, Bisht B, Hall MJ, et al. A multimodal, nonpharmacologic intervention improves mood and cognitive function in people with multiple sclerosis. J Am Coll Nutr. 2017;36(3):150-168.
  • Ota M, Matsuo J, Ishida I, et al. Effects of a medium-chain triglyceride-based ketogenic formula on cognitive function in patients with mild-to-moderate Alzheimer’s disease. Neurosci Lett. 2019;690:232-236.